Amgen’s dazodalibep cuts disease activity in phase‑3 Sjögren’s trial

Amgen reported that its CD40L antagonist dazodalibep significantly lowered systemic disease activity in patients with moderate‑to‑severe Sjögren’s disease in the phase‑3 OASIZ‑301 trial. The 1,500 mg every‑4‑weeks dose reduced the ESSDAI score by 5.6 points versus 3.8 points with placebo, a 1.8‑point difference (adjusted P <.001). The same regimen also improved patient‑reported dryness, with placebo‑adjusted differences of –1.17 points on the ESSPRI dryness domain and –0.93 points on the DASPRI dryness domain (adjusted P <.001). Safety was comparable across all groups.

The company says the data support dazodalibep’s potential as a first‑in‑class disease‑modifying therapy for Sjögren’s disease, a condition with no approved treatments. If approved, the drug could open a new market segment for Amgen and provide a novel option for patients.

  • 1The trial enrolled 648 patients with moderate‑to‑severe systemic disease activity (ESSDAI ≥ 5).
  • 2Mean baseline ESSDAI score was 10.2.
  • 3At week 48, the 1,500 mg every‑4‑weeks regimen reduced ESSDAI by a least‑squares mean of 5.6 points versus 3.8 points with placebo (difference = 1.8, adjusted P <.001).
  • 4The 3,000 mg every‑12‑weeks regimen reduced ESSDAI by 5.2 points versus placebo (difference = 1.4, adjusted P =.010).
  • 5The 1,500 mg regimen improved patient‑reported dryness: ESSPRI dryness domain difference = –1.17 points (adjusted P <.001) and DASPRI dryness domain difference = –0.93 points (adjusted P <.001).
  • 6Adverse events occurring in ≥5% of patients were nasopharyngitis, urinary‑tract infection, hypertension, and infusion‑related reactions, generally mild to moderate; serious adverse event rates were similar across groups.

Sources